Capillary Technologies India Ltd

Q4 FY27 Earnings Call Analysis

IT - Software

Full Stock Analysis
orderbook: Yesfundraise: No informationcapex: Yesrevenue: Category 2margin: Category 3
πŸ—οΈ

capex

Any current/future capex/capital investment/strategic investment?

- Capillary is continuing investments in AI product development, which has been delivering good results and improving productivity for both Capillary and its customers. - Ongoing investment in product enhancements to facilitate smoother customer migrations from legacy platforms to the Capillary platform, particularly for acquired customers. - No new products are currently planned, but the company will update stakeholders as and when new products are developed. - Technology and corporate costs, which form a significant part of expenses, have decreased as a percentage of revenue, indicating ongoing investment efficiency. - The company has made acquisitions (fourth acquisition being Kognitiv in May) and plans further M&A activity, focusing on migrating acquired customers to Capillary’s platform to realize margin and efficiency gains.
πŸ“Š

revenue

Future growth expectations in sales/revenue/volumes?

- Revenue grew 16% year-on-year in Q3 FY26, with 22% growth for the nine months period. - Annual Recurring Revenue (ARR) increased by 21% over March 2025 for the nine months FY26. - New order book increased from INR 53 crores to INR 66 crores in the first nine months, indicating growth in new customer wins. - Net Retention Rate (NRR) for organic customers at 115%, demonstrating strong expansion within the existing customer base. - 12 new customers added over nine months, with three in the last quarter. - Growth driven by three axes: strong net retention, new customer acquisition, and M&A-driven customer migration. - M&A strategy involves acquiring low-margin competitors and migrating their customers onto higher-margin Capillary platform to improve revenues and margins. - Capillary continues to invest in AI and product innovation (e.g., aiRA) to boost win rates and enter adjacent markets, potentially enhancing future revenue streams.
πŸ“ˆ

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- EBITDA improved significantly from -4% in FY23 to about 12% in FY25 and is expected to continue improving due to economies of scale. - Technology and corporate costs have reduced from 28% of revenue to about 18%, indicating further leverage potential. - Majority of costs (~60%) are fixed (tech, product, sales, marketing) and expected to grow near inflation plus team growth, supporting margin expansion. - Continued investments in AI-led product enhancements and customer migrations are planned, balancing growth and cost control. - New customer additions and organic net retention rate (NRR) of 115% indicate strong revenue growth and margin improvement. - Acquisitions will continue with margin-enhancing customer platform migrations driving profitability. - Overall, profitable growth with improving EBITDA margins and operating leverage is expected, with PAT normalized for one-time costs showing stability and potential for growth.
πŸ“‹

orderbook

Current/ Expected Orderbook/ Pending Orders?

- Over the first nine months of FY26, Capillary Technologies added 12 new customers. - In the last quarter alone, 3 new customers were added. - New order book value added over the 9-month period is INR 66 crores. - This represents growth compared to INR 53 crores new order book added in the same period last year. - The company continues to grow its new order book steadily, indicating a healthy pipeline of new business.
πŸ’°

fundraise

Any current/future new fundraising through debt or equity?

- The transcript provided (up to page 16) does not mention any current or planned future fundraising through debt or equity. - No explicit discussion on raising new capital via debt or equity is noted in the Q&A or management commentary. - The company highlights a strong cash position with INR 463 crores cash balance and positive operating cash flows. - Focus appears to be on organic growth, product investments, and acquisitions rather than new fundraising rounds. - No specific disclosures or guidance regarding fundraising plans are provided in the material reviewed.